Android app Apple app link

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan

By Yahoo! Finance   |   4 weeks ago
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan

Cytokinetics, Inc. (NASDAQ: CYTK) is rated "Overweight" by JPMorgan despite a price target reduction. Aficamten's slower launch trajectory affects revenue projections, but its unique profile and clinical outcomes remain promising.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.